Malak Alharbi, Assistant Professor at King AbdulAziz University, shared on LinkedIn:
“Healthcare professionals involved in cancer care – we would love to hear from you!
Biosimilars have the potential to improve access to effective cancer treatments, reduce costs, and ultimately help address disparities in cancer care.
We are currently conducting a research study to better understand healthcare professionals’ knowledge, experience, and perspectives on biosimilar use in oncology and hematology, as well as the barriers that may influence their adoption in clinical practice.”
You can also read:
FDA Clears a Quicker Path for Biosimilars to Cut Prices
